CClinicalTrials.gg
CompletedNCT00830375Updated Jul 29, 2019Results posted

Memantine Treatment of Compulsive Buying

A Phase 2 interventional study of Memantine in Compulsive Buying, sponsored by University of Minnesota. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-29.

Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Read the detailed description

The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

02

Conditions studied

  • Compulsive Buying

Keywords

  • Buying
  • Shopping
  • Impulse Control
03

In context

Lead sponsor

University of Minnesota is the lead sponsor of 1,184 studies on the registry; 195 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 91 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. men and women age 18-65
  2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB)
  3. buying behavior within 2 weeks prior to enrollment

Exclusion criteria

Exclusion Criteria:

  1. infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB
  2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen
  3. history of seizures
  4. myocardial infarction within 6 months
  5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions;
  7. clinically significant suicidality;
  8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence
  9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID
  10. current or recent (past 3 months) DSM-IV substance abuse or dependence;
  11. positive urine drug screen at screening
  12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline
  13. previous treatment with memantine
  14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Memantine

    10-30mg, memantine

    Drug: Memantine

Interventions

  • DrugMemantine

    10-30mg, by mouth, daily

    Also known as: Namenda

06

What researchers measure

Primary outcomes

  1. Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)

    The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms

    Time frame: from study start to study end (8-weeks) and is Investigator rated

07

Results

Posted May 4, 2012

Participant flow

December 2008 - August 2010

Participant flow — Overall Study
MilestoneMemantine
Started10
Completed9
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryYale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)

The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms

Time frame:
from study start to study end (8-weeks) and is Investigator rated
Reported as:
Mean · units on a scale
Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)
units on a scaleMemantine
Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)22 ± 4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine—0/10 (0%)0/10 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Memantine
<=18 years0
Between 18 and 65 years10
>=65 years0
Age, Continuous
Age, Continuous(years)Memantine
Mean32 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Memantine
Female9
Male1
Region of Enrollment
Region of Enrollment(participants)Memantine
United States10
08

Study locations

2 sites
  • Ambulatory Research Center
    Minneapolis, Minnesota 55454, United States
  • University of Minnesota
    Minneapolis, Minnesota 55454, United States
09

References and documents

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00830375
Lead sponsor
University of Minnesota
Responsible party
Sponsor
First posted
Jan 27, 2009
Start date
Dec 1, 2008
Primary completion
Aug 1, 2010
Completion
Aug 1, 2010
Results posted
May 4, 2012
Last update
Jul 29, 2019

Study contacts

Jon Grant, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion